JP2023550739A5 - - Google Patents
Info
- Publication number
- JP2023550739A5 JP2023550739A5 JP2023529966A JP2023529966A JP2023550739A5 JP 2023550739 A5 JP2023550739 A5 JP 2023550739A5 JP 2023529966 A JP2023529966 A JP 2023529966A JP 2023529966 A JP2023529966 A JP 2023529966A JP 2023550739 A5 JP2023550739 A5 JP 2023550739A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- carboxamide
- oxazole
- methylpyridine
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115317P | 2020-11-18 | 2020-11-18 | |
| US63/115,317 | 2020-11-18 | ||
| PCT/US2021/059668 WO2022108996A1 (en) | 2020-11-18 | 2021-11-17 | Methods of treating diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550739A JP2023550739A (ja) | 2023-12-05 |
| JP2023550739A5 true JP2023550739A5 (enExample) | 2024-11-22 |
Family
ID=81709660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529966A Pending JP2023550739A (ja) | 2020-11-18 | 2021-11-17 | 疾患及び障害を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230414582A1 (enExample) |
| EP (1) | EP4248212A4 (enExample) |
| JP (1) | JP2023550739A (enExample) |
| KR (1) | KR20230110729A (enExample) |
| CN (1) | CN116710776A (enExample) |
| AU (1) | AU2021381324A1 (enExample) |
| CA (1) | CA3199157A1 (enExample) |
| IL (1) | IL302869A (enExample) |
| MX (1) | MX2023005591A (enExample) |
| WO (1) | WO2022108996A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| IL300310A (en) * | 2020-08-03 | 2023-04-01 | Curis Inc | Preparations and methods for treating diseases and disorders |
| KR20230107866A (ko) * | 2020-11-20 | 2023-07-18 | 베이진 스위찰랜드 게엠베하 | Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법 |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| JP2025516501A (ja) * | 2022-05-11 | 2025-05-30 | キュリス，インコーポレイテッド | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
| KR20260018053A (ko) * | 2023-06-01 | 2026-02-06 | 쿠리스 인코퍼레이션 | Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| CN108024971A (zh) * | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| EP3600270B1 (en) * | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| HUE067356T2 (hu) * | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
-
2021
- 2021-11-17 MX MX2023005591A patent/MX2023005591A/es unknown
- 2021-11-17 CA CA3199157A patent/CA3199157A1/en active Pending
- 2021-11-17 US US18/037,697 patent/US20230414582A1/en active Pending
- 2021-11-17 EP EP21895491.5A patent/EP4248212A4/en active Pending
- 2021-11-17 CN CN202180076913.XA patent/CN116710776A/zh active Pending
- 2021-11-17 WO PCT/US2021/059668 patent/WO2022108996A1/en not_active Ceased
- 2021-11-17 AU AU2021381324A patent/AU2021381324A1/en active Pending
- 2021-11-17 IL IL302869A patent/IL302869A/en unknown
- 2021-11-17 JP JP2023529966A patent/JP2023550739A/ja active Pending
- 2021-11-17 KR KR1020237016600A patent/KR20230110729A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550739A5 (enExample) | ||
| ES3054136T3 (en) | Irak degraders and uses thereof | |
| RU2453548C2 (ru) | Азаиндолы, полезные в качестве ингибиторов янус-киназ | |
| CN107912040B (zh) | 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物 | |
| EP3600270B1 (en) | Compounds and compositions for treating hematological disorders | |
| US10258603B2 (en) | Therapeutic compounds and uses thereof | |
| CN107873032B (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| CN114732910B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| US10968203B2 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | |
| UA130639C2 (uk) | Похідні сечовини, корисні для лікування онкологічного захворювання | |
| TW200911811A (en) | Imidazopyrazines as protein kinase inhibitors | |
| WO2014145015A2 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| HK1248235A1 (zh) | 具有作为吲哚胺2，3-二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物 | |
| TW201242967A (en) | Imidazopyridine derivatives as PI3K inhibitors | |
| JP2014510794A (ja) | ＩＫＫ関連キナーゼεおよびＴＡＮＫ結合キナーゼ１の阻害剤の組成物および治療的使用 | |
| TW201244719A (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| KR20220004726A (ko) | Jak 억제제로서의 치환된 피롤로피리딘 | |
| JP2023537477A5 (enExample) | ||
| CN116710776A (zh) | 治疗疾病和病症的方法 | |
| CN119156458A (zh) | 用irak4修饰化合物治疗疾病和病症 | |
| CA2975372A1 (en) | Preventive and/or therapeutic agent of immune disease | |
| HK40096682A (zh) | 治疗疾病和病症的方法 | |
| CN120239604A (zh) | 治疗白血病的方法 | |
| HK40120966A (zh) | 用irak4修饰化合物治疗疾病和病症 | |
| CN104788365A (zh) | 异烟酰胺衍生物、其制备方法及应用 |